EMBIOSYS INC.

North Andover, MA

OncologyGrant-only

What changed

NIH R44 · $1.4M · CuRrEnT: Capecitabine in RCB2/3 with a wearable induced Electric field device in Triple Negative Breast Cancer

10mo agoNew grantSep 17, 2025Source filing (opens the source filing in a new tab)

Momentum

37no change

Little recent filing activity, or the events on file have decayed.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Grant-only

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

12,063 pre-ticker oncology companies at Grant-only

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Grant
R44 · $1.4M · non-dilutive
Sep 17, 2025
EMBIOSYS INC. · PI BARRON, CHRISTOPHER · NCI · award ends Aug 31, 2027 · CuRrEnT: Capecitabine in RCB2/3 with a wearable induced Electric field device in Triple Negative Breast Cancer
NIH RePORTER · NIH RePORTER 11313323 (opens the source filing in a new tab)
Grant
R43 · $189k · non-dilutive
Jun 1, 2024
EMBIOSYS INC. · PI BARRON, CHRISTOPHER · NCI · award ends Aug 31, 2026 · DEVELOPMENT OF A WEARABLE, NON-INVASIVE, TREATMENT DEVICE FOR METASTATIC TRIPLE-NEGATIVE BREAST CANCER (TNBC)
NIH RePORTER · NIH RePORTER 11086646 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 58%Edges merged automatically, not yet reviewed by a human

Semantic similarity of the underlying science links the grant record at 0.87name similarity 100% · semantic similarity 96% · same city · same therapeutic area
new_entity links the grant record at 0.28same therapeutic area

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Investigators

The principal investigators named on the grants below. Each links to their federal grant record and every other company traced to their work.

Christopher Barron

Event stream

Every scored event, newest first. This is what momentum is computed from.

NIH R44 · $1.4M · CuRrEnT: Capecitabine in RCB2/3 with a wearable induced Electric field device in Triple Negative Breast Cancer
10mo agoNew grantSource (opens the source filing in a new tab)
NIH R43 · $0.2M · DEVELOPMENT OF A WEARABLE, NON-INVASIVE, TREATMENT DEVICE FOR METASTATIC TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Jun 2025Grant renewalSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Peer position

Grant to raise

R44 · $1.4M · non-dilutive

R43 · $189k · non-dilutive